NCT02594865已完成不适用
Glucerna in Critically Ill Patients (GluCip Trial): Investigating the Glycaemic Effects of a Reduced-carbohydrate, Modified-fat, Fiber-containing Enteral Formula (Glucerna®) in Critically Ill Patients.
PHJ van der Voort2 个研究点 分布在 1 个国家目标入组 100 人开始时间: 2015年9月1日最近更新:
适应症
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 发起方
- 入组人数
- 100
- 试验地点
- 2
- 主要终点
- Glucose variability
研究概览
简要总结
To investigate whether the administration of Glucerna achieves less glycaemic variability, defined as the mean absolute glucose (MAG) change, and better glycaemic control compared to a standard high-carbohydrate enteral formula. Continuous glucose monitoring technology will be used to evaluate glycaemic variability and glycaemic control.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Age ≥ 18 years;
- •Patients with an anticipated stay of at least 48 hours of admission to the intensive care
- •Expected to receive enteral feeding for at least 48 hrs
- •Indication for glucose regulation with insulin (according to the current glucose treatment protocol)
- •Patient or surrogate understands and signs informed consent document.
排除标准
- •Patients with pre-existing contraindications to enteral feeding or to placement of a continuous glucose monitoring system
- •Patients previously randomised into the GluCip trial
- •Any disease or condition which the investigator or treating physician feels would interfere with the trial or the safety of the patient.
结局指标
主要结局
Glucose variability
时间窗: 72 hours
The primary outcome is the extent of glucose variability, defined as the mean absolute glucose (MAG) change (delta glucose/delta time) in mmol/l/hr.
次要结局
- Amount of insulin use(72 hours)
- Duration of severe hypoglycemic events(72 hours)
- Number of severe hypoglycemic events(72 hours)
- Mean glucose and standarddeviation(72 hours)
- Duration of severe hyperglycemic events(72 hours)
- Daily calorie administration(72 hours)
- Daily nutrient administration(72 hours)
- Time in target range(72 hours)
- Number of severe hyperglycemic events(72 hours)
研究者
PHJ van der Voort
Prof., MD, PhD, MSc
Onze Lieve Vrouwe Gasthuis
研究点 (2)
Loading locations...
相似试验
已完成
不适用
Glucerna in Critically ill Patients (GluCip trial): Investigating the glycaemic effects of a reduced-carbohydrate, modified-fat, fiber-containing enteral formula (Glucerna®) in critically ill patients.glucose variabilitystress-hyperglycaemia10018424diabetesNL-OMON42200Onze Lieve Vrouwe Gasthuis90
Unknown
不适用
Comparative Study of GlySure Continuous Intra-vascular Glucose Monitoring and Intermittent Monitoring in Medical ICUBlood Glucose Monitoring in Medical ICUNCT02142088GlySure60
已完成
不适用
Usability of Blood Glucose Control With the Space TGC System in Medical ICU PatientsCritical IllnessNCT01164449B. Braun Melsungen AG20
终止
2 期
iberal blood glucose control in critically ill patients with pre-existing type 2 diabetes.Critical illnessMetabolic and Endocrine - DiabetesType 2 DiabetesACTRN12616001135404Royal Adelaide Hospital436
Unknown
4 期
A Trial Comparing SGC and Conventional Empiric Treatment for Glucose Control in Critically Ill Patients With Mechanical Ventilation in ICUCritical IllnessRespiratory FailureHyperglycemiaNCT02491346Peking Union Medical College Hospital46